Effects of zotepine, norzotepine, and other reference antipsychotics on APO-induced climbing and gnawing in mice
| Compounds | Doses | n | Climbing | Gnawing Score | ||
|---|---|---|---|---|---|---|
| Climbing Time | Inhibition | ED50 | ||||
| mg/kg i.p. | s | % | mg/kg i.p. | |||
| Norzotepine | APO(−) | 8 | 9.4 ± 5.9### | 100 | 0 ± 0 | |
| 0 | 8 | 111 ± 6.1 | 0 | 3.9 | 0.8 ± 0.4 | |
| 1 | 8 | 106 ± 15 | 5.5 | 0.9 ± 0.4 | ||
| 3 | 8 | 90 ± 18 | 21 | 1.9 ± 0.1* | ||
| 10 | 8 | 13 ± 13*** | 97 | 1.3 ± 0.4 | ||
| Zotepine | APO(−) | 8 | 6.1 ± 6.1### | 100 | 0 ± 0 | |
| 0 | 8 | 111 ± 6.6 | 0 | 0.73 | 0.5 ± 0.3 | |
| 0.3 | 8 | 90 ± 20 | 20 | 0.6 ± 0.3 | ||
| 1 | 8 | 53 ± 21* | 55 | 0.3 ± 0.3 | ||
| 3 | 8 | 0 ± 0*** | 106 | 0 ± 0 | ||
| Olanzapine | APO(−) | 8 | 0 ± 0### | 100 | 0 ± 0 | |
| 0 | 8 | 119 ± 0.8 | 0 | 0.67 | 0.3 ± 0.3 | |
| 0.1 | 8 | 117 ± 1.8 | 1.5 | 0.4 ± 0.3 | ||
| 0.3 | 8 | 120 ± 0 | −0.8 | 0 ± 0 | ||
| 1 | 8 | 30 ± 20*** | 75 | 0 ± 0 | ||
| Risperidone | APO(−) | 8 | 8.8 ± 7.2### | 100 | 0 ± 0 | |
| 0 | 8 | 116 ± 2.9 | 0 | 0.036 | 0.4 ± 0.3 | |
| 0.01 | 8 | 105 ± 15 | 10 | 0.9 ± 0.4 | ||
| 0.03 | 8 | 86 ± 18 | 28 | 0.5 ± 0.3 | ||
| 0.1 | 8 | 15 ± 15*** | 94 | 0 ± 0 | ||
| Amisulpride | APO(−) | 7 | 0 ± 0### | 100 | 0 ± 0 | |
| 0 | 7 | 120 ± 0.3 | 0 | 33 | 0.6 ± 0.4 | |
| 10 | 7 | 94 ± 18 | 22 | 1.7 ± 0.2* | ||
| 30 | 7 | 17 ± 17*** | 86 | 1.9 ± 0.1** | ||
| 100 | 7 | 0 ± 0*** | 100 | 0.3 ± 0.3 | ||
All compounds were injected intraperitoneally 20 min before APO treatment (2 mg/kg, s.c.).
↵* , P < 0.05;
↵** , P < 0.01;
↵*** , P < 0.001; statistically significant compared with APO alone-treated control group (0), as assessed with Dunnett's multiple comparison test.
↵### , P < 0.001; statistically significant compared with APO alone-treated control group as assessed using Student's t test. Climbing time and gnawing score criteria are described under Materials and Methods, and data are shown as mean ± S.E.M.